Fluor Corporation has secured an engineering, procurement and construction contract to for a new US$2 billion medical manufacturing facility in North Carolina.
The contracted, awarded by Novo Nordisk, calls on Fluor to deliver a 77,000 m2 facility from which life-saving medicines will be produced for diabetes sufferers.
Since the project was announced earlier this year, Fluor has been working with Novo Nordisk, providing basic design services.
With completion of the project expected in mid-2019, some 2,500 people are expected to be employed on the construction, with 700 jobs made available at the facility, once in full operation.
Juan G. Hernández, president of Fluor's Life Sciences and Advanced Manufacturing business, said, "Fluor is honoured to have the opportunity to assist Novo Nordisk in building this world-class facility in North Carolina to provide modern treatments to diabetes patients.”
He added, “This project is the single largest life sciences facility investment in North Carolina's history, which fits well with Fluor's legacy of building numerous significant life sciences and manufacturing projects in the southeast United States."
Morten Nielsen, Novo Nordisk’s senior vice president, said, "Novo Nordisk selected Fluor for this critical project, the largest in our history, based on their strong safety culture, technical competence in the life sciences industry and ability to deliver the full scope of work,"